Call Us:  954-929-4814

If the phone line is busy, please call 954-929-4895 or email us

Monitors gastrointestinal, pancreatic, liver, and colorectal malignancies.

CA 19-9, a carbohydrate antigen related to Lewis blood group antigen, has been shown to be elevated in serum of some patients with gastrointestinal tumors. CA 19-9, as a tumor marker, is helpful in post-therapeutic monitoring to determine the success of therapy or the development of recurrence when used serially.

CA 19-9 has been reported as positive in 70% to 80% of pancreatic carcinomas, 50% to 60% of gastric cancers, 60% of hepatobiliary cancer, 30% of colorectal cancer, and few lung, breast or prostate cancers.

Serum levels may differentiate pancreatic cancer from pancreatitis. The test may also be positive in patients with non-neoplastic disease, particularly inflammatory disease of the bowel, cirrhosis, and autoimmune conditions including rheumatoid arthritis (33%), systemic lupus erythematosus (32%), and scleroderma (33%).

Methodology: Siemens chemiluminescent assay.

Normal range is less than 35 U/mL.

Values obtained with different assay methods should not be used interchangeably.

CA 19-9 Gastric, Pancreatic Tumor Marker

Cancer testing Cancer Profile hcg testing navarro test Emil K. Schandl Dr. E. K. Schandl Longevity Profile cancer tests anti-aging tests Dr. Schandl cancer prevention cancer treatment management cancer therapy follow up cancer detection early detection and prevention prevention oncoblot test AMAS test circulating tumor cells cancer marker test tumor marker test